BioNTech SE ADR [BNTX] stock is trading at $122.78, up 9.73%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BNTX shares have gain 2.37% over the last week, with a monthly amount glided 9.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on January 10, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $172. Previously, Wells Fargo started tracking the stock with Overweight rating on December 11, 2024, and set its price target to $170. On December 02, 2024, BMO Capital Markets reiterated its Outperform rating. Evercore ISI upgraded its rating to a Outperform and increased its price target to $125 on November 19, 2024. Berenberg initiated its recommendation with a Buy and recommended $130 as its price target on November 19, 2024. Goldman upgraded its rating to Buy for this stock on November 08, 2024, and upped its price target to $137. In a note dated September 24, 2024, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $93 to $145.
BioNTech SE ADR [BNTX] stock has fluctuated between $76.53 and $131.49 over the past year. Currently, Wall Street analysts expect the stock to reach $136.29 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $122.78 at the most recent close of the market. An investor can expect a potential return of 11.0% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
BioNTech SE ADR [NASDAQ:BNTX] reported sales of 3.30B for the trailing twelve months, which represents a growth of 40.41%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.23%, Pretax Profit Margin comes in at -0.11%, and Net Profit Margin reading is -0.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.02 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 116.60 points at the first support level, and at 110.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 125.94, and for the 2nd resistance point, it is at 129.10.
Ratios To Look Out For
For context, BioNTech SE ADR’s Current Ratio is 7.33. Further, the Quick Ratio stands at 7.21, while the Cash Ratio is 3.81. Considering the valuation of this stock, the price to sales ratio is 8.92, the price to book ratio is 1.38.
Transactions by insiders
Recent insider trading involved ATHOS KG, 10% Owner, that happened on Dec 13 ’24 when 4983.0 shares were purchased. 10% Owner, ATHOS KG completed a deal on Dec 11 ’24 to buy 22450.0 shares. Meanwhile, 10% Owner ATHOS KG bought 53716.0 shares on Dec 09 ’24.
